V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213531 | 20079961 | 1.57 | 74 | Palliative (P) | 2018-05-08 | 2018-05-25 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100766596 |
| 20213532 | 20079962 | 0 | 90 | Palliative (P) | 2021-05-11 | 2021-05-12 | LANREOTIDE | 02 | N | LANREOTIDE | 101332798 |
| 20213533 | 20079963 | 1.75 | 0 | Palliative (P) | 2017-04-29 | 2017-05-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100494938 |
| 20213534 | 20079964 | 1.6 | 81.4 | Palliative (P) | 2018-03-17 | 2018-03-27 | GO2 TRIAL | Y | N | TRIAL | 100070133 |
| 20213535 | 20079965 | 1.64 | 68 | Palliative (P) | 2018-04-21 | 2018-05-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101394885 |
| 20213536 | 20079966 | null | null | Disease modification (D) | 2019-12-13 | 2020-01-24 | TCX | 02 | N | LANREOTIDE | 101062151 |
| 20213537 | 20079967 | 1.83 | 84.5 | Palliative (P) | 2019-01-18 | 2019-02-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101818668 |
| 20213538 | 20079968 | 1.66 | null | Palliative (P) | 2019-10-02 | 2019-10-02 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101557184 |
| 20213539 | 20079969 | 1.8 | 127 | Curative (C) | 2018-04-15 | 2018-04-29 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100024261 |
| 20213540 | 20079970 | null | 66.75 | Palliative (P) | 2017-06-29 | 2017-07-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100677644 |
| 20213541 | 20079971 | 1.82 | 80.7 | Curative (C) | 2019-09-04 | 2019-09-05 | Cetuximab + FOLFIRI cycle1 | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101684475 |
| 20213542 | 20079972 | 1.59 | 65.4 | Curative (C) | 2019-06-30 | 2019-07-27 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101180760 |
| 20213543 | 20079973 | 1.56 | 64 | null | 2017-06-04 | 2017-06-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101303199 |
| 20213544 | 20079974 | 1.86 | 66 | Curative (C) | 2018-09-12 | 2018-10-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100590714 |
| 20213545 | 20079975 | 1.78 | 65.3 | Curative (C) | 2017-12-01 | 2017-12-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101500758 |
| 20213548 | 20079977 | 1.55 | 38.35 | Curative (C) | 2018-05-26 | 2018-05-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100101557 |
| 20213549 | 20079978 | 1.68 | 80.5 | Curative (C) | 2016-12-01 | 2016-12-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101499719 |
| 20213550 | 20079979 | 1.62 | 79.8 | Palliative (P) | 2018-07-20 | 2018-07-23 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101321525 |
| 20213551 | 20079980 | 1.64 | 71.8 | Palliative (P) | 2018-09-24 | 2018-10-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101547047 |
| 20213552 | 20079981 | 1.58 | 0 | Curative (C) | 2018-06-03 | 2018-06-10 | Fluorouracil+Mitomycin+RT (Bladder) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101567283 |
| 20213554 | 20079983 | null | 97 | 02 | 2019-05-12 | 2019-05-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101178944 |
| 20213555 | 20079984 | 1.61 | 61 | Palliative (P) | 2019-12-06 | 2019-12-13 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101622761 |
| 20213556 | 20079985 | 1.72 | 90.8 | Palliative (P) | 2016-10-05 | 2016-10-15 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101404033 |
| 20213557 | 20079986 | 1.77 | 64.2 | Palliative (P) | 2019-02-12 | 2019-02-12 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101480499 |
| 20213558 | 20079987 | 1.79 | 71.2 | Palliative (P) | 2019-09-29 | 2019-09-30 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100968830 |
| 20213561 | 20079989 | 1.8 | 69.75 | Curative (C) | 2016-11-23 | 2016-12-07 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 100968001 |
| 20213562 | 20079990 | 1.64 | 71.5 | null | 2016-07-22 | 2016-07-27 | IMATINIB | 02 | null | IMATINIB | 101237961 |
| 20213563 | 20079991 | 1.6 | 61.5 | Palliative (P) | 2018-05-17 | 2018-05-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100382590 |
| 20213564 | 20079992 | null | 103 | Curative (C) | 2016-09-26 | 2016-09-26 | Imatinib 400mg | 02 | N | IMATINIB | 101458263 |
| 20213565 | 20079993 | 1.83 | 80.8 | Curative (C) | 2017-10-21 | 2017-11-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100332817 |
| 20213566 | 20079994 | 1.5 | 84.4 | Palliative (P) | null | 2017-11-11 | Trial Unspecified | N | N | TRIAL | 101311290 |
| 20213567 | 20079995 | 1.58 | 47.9 | 03 | 2018-06-02 | 2018-06-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100590211 |
| 20213569 | 20079996 | 1.68 | 64.8 | Neo-adjuvant (N) | 2016-10-14 | 2016-10-20 | Cape+Cisplatin+Trastuzumab Main | 02 | N | TRIAL | 101179801 |
| 20213571 | 20079997 | 1.5 | 86.5 | Palliative (P) | 2017-08-10 | 2017-08-31 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101061953 |
| 20213572 | 20079998 | 1.57 | 79.8 | Curative (C) | 2018-01-01 | 2018-01-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101261920 |
| 20213573 | 20079999 | 1.65 | 50.1 | Curative (C) | 2017-12-25 | 2018-01-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101580813 |
| 20213574 | 20080000 | 1.65 | 61.5 | Neo-adjuvant (N) | 2018-11-21 | 2018-12-05 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100168456 |
| 20213575 | 20080001 | 1.64 | 74 | Disease modification (D) | 2018-03-11 | 2018-03-20 | HCX (Cape + Cisp + Tras) - Main | 02 | N | IMATINIB | 100186875 |
| 20213577 | 20080003 | 1.62 | 68 | Curative (C) | 2017-04-12 | 2017-04-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100439753 |
| 20213579 | 20080005 | 1.53 | null | Palliative (P) | 2017-08-07 | 2017-08-14 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100461810 |
| 20213580 | 20080006 | 1.85 | 63 | Palliative (P) | 2017-10-30 | 2017-10-30 | IMATINIB | 02 | N | IMATINIB | 100442236 |
| 20213581 | 20080007 | 1.74 | 67.2 | Palliative (P) | 2017-12-01 | 2017-12-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101334751 |
| 20213583 | 20080008 | 1.68 | 79.2 | Palliative (P) | 2019-01-28 | 2019-02-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100017394 |
| 20213584 | 20080009 | 1.7 | 73.5 | Palliative (P) | 2018-06-12 | 2018-06-12 | IMATINIB | N | N | IMATINIB | 100971313 |
| 20213585 | 20080010 | 1.6 | 113 | Neo-adjuvant (N) | 2017-03-02 | 2017-03-03 | Trial Unspecified | 1 | N | TRIAL | 101744742 |
| 20213587 | 20080011 | 1.67 | 74 | Palliative (P) | 2018-12-16 | 2018-12-16 | Imatinib 200mg | 02 | N | IMATINIB | 100892802 |
| 20213588 | 20080012 | 1.62 | 59 | null | 2016-04-01 | 2016-04-14 | HCX | 02 | null | LANREOTIDE | 101389086 |
| 20213589 | 20080013 | 1.75 | 79 | Palliative (P) | 2018-09-16 | 2018-09-26 | LANREOTIDE | 02 | N | LANREOTIDE | 100368827 |
| 20213590 | 20080014 | 1.8 | 70.2 | Disease modification (D) | 2020-06-29 | 2020-06-29 | LANREOTIDE | 02 | N | LANREOTIDE | 101651974 |
| 20213591 | 20080015 | 1.7 | 73 | Curative (C) | null | 2016-11-04 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100592337 |